HES V2.0: Advancing biomarker-based surveillance for HCC - promise and remaining gaps.
APA
Peng N, Lee IC, et al. (2026). HES V2.0: Advancing biomarker-based surveillance for HCC - promise and remaining gaps.. Journal of hepatology, 84(3), 490-492. https://doi.org/10.1016/j.jhep.2025.10.025
MLA
Peng N, et al.. "HES V2.0: Advancing biomarker-based surveillance for HCC - promise and remaining gaps.." Journal of hepatology, vol. 84, no. 3, 2026, pp. 490-492.
PMID
41197907
같은 제1저자의 인용 많은 논문 (5)
- Foundations of Artificial Intelligence in Hepatology: What a Clinician Needs to Know.
- Hepatitis viruses hijack cellular metabolic pathways to drive replication and disease: Implications for novel therapeutics.
- Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.
- "Sample-in, result-out" liquid biopsy chip based on immunomagnetic separation and CRISPR detection for multiplex analysis of exosomal microRNAs.
- PARP inhibitors for HRR-deficient metastatic castration-resistant prostate cancer: mechanisms and clinical strategies.